Danaher Co. (NYSE:DHR) Shares Acquired by Stonegate Investment Group LLC

Stonegate Investment Group LLC lifted its holdings in shares of Danaher Co. (NYSE:DHR) by 2.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 225,199 shares of the conglomerate’s stock after buying an additional 4,830 shares during the period. Danaher makes up approximately 1.4% of Stonegate Investment Group LLC’s holdings, making the stock its 28th largest position. Stonegate Investment Group LLC’s holdings in Danaher were worth $51,694,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. FMR LLC raised its holdings in Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares in the last quarter. International Assets Investment Management LLC raised its holdings in Danaher by 40,196.5% during the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after purchasing an additional 428,897 shares in the last quarter. Montrusco Bolton Investments Inc. increased its holdings in Danaher by 30.4% in the third quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after buying an additional 397,671 shares in the last quarter. Finally, Union Bancaire Privee UBP SA purchased a new position in Danaher in the fourth quarter valued at about $74,551,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DHR. Royal Bank of Canada dropped their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. KeyCorp increased their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Evercore ISI increased their target price on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Stifel Nicolaus increased their target price on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday, October 23rd. Finally, Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research note on Friday, December 13th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Stock Up 1.9 %

Shares of NYSE DHR opened at $250.51 on Tuesday. Danaher Co. has a 1 year low of $225.42 and a 1 year high of $281.70. The firm’s 50 day moving average price is $235.33 and its 200 day moving average price is $253.62. The firm has a market cap of $180.94 billion, a P/E ratio of 47.81, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.